271 related articles for article (PubMed ID: 29099770)
1. Adenosine A
Asano T; Takenaga M
J Clin Med; 2017 Nov; 6(11):. PubMed ID: 29099770
[TBL] [Abstract][Full Text] [Related]
2. Main ion channels and receptors associated with visceral hypersensitivity in irritable bowel syndrome.
de Carvalho Rocha HA; Dantas BP; Rolim TL; Costa BA; de Medeiros AC
Ann Gastroenterol; 2014; 27(3):200-206. PubMed ID: 24976114
[TBL] [Abstract][Full Text] [Related]
3. Nerve growth factor and diarrhea-predominant irritable bowel syndrome (IBS-D): a potential therapeutic target?
Xu XJ; Liu L; Yao SK
J Zhejiang Univ Sci B; 2016 Jan; 17(1):1-9. PubMed ID: 26739521
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea.
Colomier E; Algera J; Melchior C
Front Pharmacol; 2020; 11():629026. PubMed ID: 33679391
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article.
Chen L; Ilham SJ; Feng B
Anesth Pain Med; 2017 Apr; 7(2):e42747. PubMed ID: 28824858
[TBL] [Abstract][Full Text] [Related]
6. The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments.
Farzaei MH; Bahramsoltani R; Abdollahi M; Rahimi R
J Neurogastroenterol Motil; 2016 Oct; 22(4):558-574. PubMed ID: 27431236
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of brain-derived neurotrophic factor is correlated with visceral hypersensitivity in patients with diarrhea-predominant irritable bowel syndrome.
Zhang Y; Qin G; Liu DR; Wang Y; Yao SK
World J Gastroenterol; 2019 Jan; 25(2):269-281. PubMed ID: 30670915
[TBL] [Abstract][Full Text] [Related]
8. Visceral hypersensitivity in irritable bowel syndrome.
Kanazawa M; Hongo M; Fukudo S
J Gastroenterol Hepatol; 2011 Apr; 26 Suppl 3():119-21. PubMed ID: 21443723
[TBL] [Abstract][Full Text] [Related]
9. Altered profiles of fecal metabolites correlate with visceral hypersensitivity and may contribute to symptom severity of diarrhea-predominant irritable bowel syndrome.
Zhang WX; Zhang Y; Qin G; Li KM; Wei W; Li SY; Yao SK
World J Gastroenterol; 2019 Nov; 25(43):6416-6429. PubMed ID: 31798278
[TBL] [Abstract][Full Text] [Related]
10. Irritable bowel syndrome: update on pathogenesis and management.
Alaradi O; Barkin JS
Med Princ Pract; 2002; 11(1):2-17. PubMed ID: 12116690
[TBL] [Abstract][Full Text] [Related]
11. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes.
Hughes PA; Harrington AM; Castro J; Liebregts T; Adam B; Grasby DJ; Isaacs NJ; Maldeniya L; Martin CM; Persson J; Andrews JM; Holtmann G; Blackshaw LA; Brierley SM
Gut; 2013 Oct; 62(10):1456-65. PubMed ID: 22767422
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.
Binienda A; Storr M; Fichna J; Salaga M
Curr Drug Targets; 2018; 19(15):1774-1781. PubMed ID: 29284389
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Serum sTREM-1 as a Marker of Subclinical Inflammation in Diarrhea-Predominant Patients with Irritable Bowel Syndrome.
Du C; Peng L; Kou G; Wang P; Lu L; Li Y
Dig Dis Sci; 2018 May; 63(5):1182-1191. PubMed ID: 29516326
[TBL] [Abstract][Full Text] [Related]
14. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.
Yu FY; Huang SG; Zhang HY; Ye H; Chi HG; Zou Y; Lv RX; Zheng XB
World J Gastroenterol; 2016 Mar; 22(12):3451-9. PubMed ID: 27022227
[TBL] [Abstract][Full Text] [Related]
16. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
[TBL] [Abstract][Full Text] [Related]
17. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome.
Keszthelyi D; Troost FJ; Masclee AA
Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(2):G141-54. PubMed ID: 22595988
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in pharmacological research on the management of irritable bowel syndrome.
Nam Y; Min YS; Sohn UD
Arch Pharm Res; 2018 Oct; 41(10):955-966. PubMed ID: 30132170
[TBL] [Abstract][Full Text] [Related]
19. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
Johnston JM; Shiff SJ; Quigley EM
Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.
Chey WD; Maneerattaporn M; Saad R
Gut Liver; 2011 Sep; 5(3):253-66. PubMed ID: 21927652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
